Scenic Biotech
CompanyNetherlands
Scenic Biotech develops 3 assets, the furthest preclinical (Galactokinase (GalK) in galactosemia). Mostly small molecule and oligonucleotide acting on ABHD18, lipid and ceramide metabolism and PLA2G15; based in Netherlands.
- 3
- Assets
- Furthest stage
- Preclinical
- Raised
- US$31m
- 0
- Trials
- 0
- Signals
Pipeline
3Allosteric covalent inhibition of galactokinase.
Preclinical, Small molecule, galactosemia
Mitochondrial modifier (ABHD18)
Preclinical, Oligonucleotide, ABHD18, cardiomyopathy
Inhibits PLA2G15 to restore lysosomal function.
Preclinical, Small molecule, Lipid and ceramide metabolism, PLA2G15, Batten disease, frontotemporal dementia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Funding rounds and grants1
- People24
- Similar companies6